Co-crystals of SGLT2 inhibitors, process for their preparation and pharmaceutical compositions thereof

Patent metadata

Field	Value
Publication number	US-10738038-B2
Application number	US-201916530476-A
Country	US
Kind code	B2
Filing date	Aug 2, 2019
Priority date	Sep 15, 2015
Publication date	Aug 11, 2020
Grant date	Aug 11, 2020

Abstract

The present invention provides solid forms of SGLT2 inhibitors, to processes for their preparation and their use in the purification of SGLT2 inhibitors and also provided pharmaceutical compositions comprising them and their use in therapy.

First claim

The invention claimed is:

1. A process for the preparation of amorphous dapagliflozin, comprising:
a) dissolving or suspending dapagliflozin co-crystals in a solvent;
b) treating the step a) reaction mass with a base or an acid;
c) optionally extracting dapagliflozin into an organic solvent;
d) removing the organic solvent to obtain a residue;
e) dissolving the residue in an organic solvent to obtain a solution;
f) adding an anti-solvent to the step e) solution or vice-versa;
g) optionally seeding the solution of step f) with amorphous dapagliflozin; and
h) isolating the amorphous dapagliflozin.

2. The process of claim 1 , wherein the dapagliflozin co-crystal used in step a) is selected from one of the group consisting of DL-pipecolic acid, D-pipecolic acid, and L-pipecolic acid.

3. The process of claim 1 , wherein the solvent of step a) is selected from one of water and a mixture of water and an organic solvent.

4. The process of claim 1 , wherein the organic solvent is selected from one or more of an alcohol and an ester.

5. The process of claim 1 , wherein base in step b) is selected from one or more of the group consisting of sodium carbonate, potassium carbonate, cesium carbonate, sodium bicarbonate, potassium bicarbonate, sodium hydroxide, potassium hydroxide, lithium hydroxide, di-isopropyl ethylamine, triethyl amine, or pyridine.

6. The process of claim 1 , wherein the organic solvent of step e) is selected from one or more of the group consisting of methyl tertiary butyl ether, tetrahydrofuran, dimethyl ether, diisopropyl ether, 1,4-dioxane, methyl acetate, ethyl acetate, isopropyl acetate, n-propyl acetate, n-butyl acetate, t-butyl acetate, methanol, ethanol, isopropanol, n-propanol, n-butanol, isobutanol, acetone, methyl ethyl ketone, methyl isobutyl ketone, or mixtures thereof.

7. The process of claim 1 , wherein the anti-solvent of step f) is selected from one of water, heptane, and cycloheptane.

Assignees

• Laurus Labs Ltd
• Laurus Labs Ltd

Inventors

• Chivukula Kameswar Rao
• Thaimattam Ram
• Bandlamudi Veeranarayana
• Padala Durga Visweswar Rao
• Gade Narapa Reddy
• Regandla Nageswar Rao
• Yasam Sivarami Reddy
• Moturu Venkata Rama Krishna Murthy
• Indukuri Venkata Sunil Kumar
• Vasireddi Uma Maheswar Rao
• Kalidindi Srihari Raju
• Chava Satyanarayana

Classifications

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• C07D409/10 Primary

  linked by a carbon chain containing aromatic rings · CPC title

• C07D309/10

  Oxygen atoms · CPC title

• C07D241/24

  Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals · CPC title

• C07D211/60

  Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals · CPC title